mRNA-1273 for COVID-19

Waitlist Available · 18+ · All Sexes · Grand Island, NE

This study is evaluating whether a vaccine made from a synthetic version of the influenza virus can be safe and effective.

See full description

About the trial for COVID-19

Eligible Conditions
COVID-19 · Coronavirus Disease 2019 (COVID‑19)

Treatment Groups

This trial involves 14 different treatments. MRNA-1273 is the primary treatment being studied. Participants will be divided into 14 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 & 3 and have had some early promising results.

Experimental Group 1
Experimental Group 2
Experimental Group 3
Show More

About The Treatment

First Studied
Drug Approval Stage
How many patients have taken this drug
Moderna COVID-19 Vaccine
FDA approved


This trial is for patients born any sex aged 18 and older. There are 3 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, agreement to continue adequate contraception or abstinence through 3 months following the vaccination, and not currently breastfeeding.
Participants must have been either previously enrolled in the mRNA-1273-P301 (COVE) study, must have received 2 doses of mRNA-1273 in that study, with their second dose at least 6 months prior to enrollment in this study (mRNA-1273-P205), and must be currently enrolled and compliant in that study (that is, has not withdrawn or discontinued early); or participant must have received 2 doses of mRNA-1273 under the EUA with their second dose at least 6 months prior to enrollment in mRNA-1273-P205; or have received a 2 dose primary series of mRNA-1273 followed by a 50 μg booster dose of mRNA-1273 in the mRNA-1273-P301 (COVE) study or under EUA at least 3 months prior to enrolment in mRNA-1273-P205; and able to provide proof of vaccination status at the time of screening (Day 1).
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Days 1, 15, 181, and 366
Screening: ~3 weeks
Treatment: Varies
Reporting: Days 1, 15, 181, and 366
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Days 1, 15, 181, and 366.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether mRNA-1273 will improve 10 primary outcomes and 3 secondary outcomes in patients with COVID-19. Measurement will happen over the course of Day 29.

Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Antibody
DAY 29
DAY 29
Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Antibody at Day 29
DAY 29
DAY 29
Seroresponse Rate of Vaccine Recipients at Day 29
DAY 29
DAY 29
GMT of Omicron-Specific Antibody (For Parts F and G only) at Day 29
DAY 29
DAY 29
Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)
Seroresponse Rate of Vaccine Recipients at Day 91 (For Part G only)
DAY 91
DAY 91
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people get covid-19 a year in the United States?

Since it has been announced that the coronavirus could be transmitted via aerosols in aerosolized droplets, there is concern for the risk of respiratory infection with coronaviruses during a global epidemic. This concern was evaluated through an internet survey of adults from the United States. The survey participants answered questions on how many total cases of COVID-19 were reported with a positive test from the CDC, with the respondents' demographic parameters. Results showed a low annual incidence of 1.8 cases per 100,000 population, which indicates that the current outbreak, even in the United States, is of a low impact.

Anonymous Patient Answer

What causes covid-19?

The current global coronavirus outbreak in 2020 is a new and unforeseen viral infection. The virus is spreading quickly to many countries and even some remote regions of the world; it is believed to be the causal agent for multiple diseases, including pneumonia and severe acute respiratory syndrome. It is also thought to be a new and underestimated public health risk in the United States, especially the elderly, pregnant and HIV-positive individuals. The disease is spreading, mostly because of international travel and trade. For a more detailed analysis, see coronavirus_2019. \n\nThe U.S. Centers for Disease Control and Prevention (CDC) has released a preliminary list of 37 names of health locations that have confirmed cases of COVID-19.

Anonymous Patient Answer

What are the signs of covid-19?

Fever and malaise were the most common symptoms. The respiratory signs are not specific and thus should not be considered to be primary symptoms of the infection. It can be a non-specific sign and may be due to the underlying medical conditions or a co-infection.

Anonymous Patient Answer

What are common treatments for covid-19?

Most commonly recommended treatments of those who tested positive for coronavirus were symptomatic treatments. However, there was variability between countries across the different types of symptoms. A randomized trial of different types of treatment is urgently needed.

Anonymous Patient Answer

Can covid-19 be cured?

There is evidence supporting that for people not on antiviral therapies with mild disease and no underlying health problems, the risk of clinical deterioration appears low in the first few weeks of symptom onset. For those with severe disease or those who are otherwise frail the risk of severe illness can be significantly increased. For people not on antiviral treatments with severe disease or who are otherwise vulnerable it remains unclear if anyone with coronavirus disease in this setting will recover from their infection. The clinical evidence is limited in the literature and further research with more participants would be beneficial as well as more rigorous testing.

Anonymous Patient Answer

What is covid-19?

The number of cases that are currently being diagnosed or treated in the health-care sector is increasing. There is no evidence that the virus is spreading among those that have not come into contact with another infected person. While there are a number of possible ways that an outbreak could start, the main mechanism is likely to be by contagion from someone with the virus.

Anonymous Patient Answer

What does mrna-1273 usually treat?

Even though it may not be an effective therapy for SARS, our data suggest that mrna-1273 may be of some value for the treatment of SARS.

Anonymous Patient Answer

How does mrna-1273 work?

The data, presented here, provides evidence that mrna-1273 has antimicrobial activity that could be of clinical relevance. For instance, mrna-1273 could help treat infections that are already difficult to treat (e.g. MRSA). However, further study is required before mrna-1273 may be developed a commercial product.

Anonymous Patient Answer

Is mrna-1273 typically used in combination with any other treatments?

In a recent study, findings suggests mrna-1273 can be used in combination with current standard of care treatments, including [immunotherapy]( and chemotherapy, in selected patients. Further randomized clinical trials are warranted to further validate these observations in patients with mrna-1273 positive NSCLC.

Anonymous Patient Answer

Does covid-19 run in families?

Results from a recent paper suggest that there is a familial pattern of disease transmission in SARS in which genetic variants may influence disease risk.

Anonymous Patient Answer

What is mrna-1273?

A-to-I editing in mRNAs, is a cellular response to infection. RNase HII-dependent mRNA editing is an antiviral response to dengue virus (DENV) infection. We demonstrate that dengue virus, which causes outbreaks in Southern Italy, induced mRNA editing in HepG2 cells. The mRNA editing process of DENV is different from the type I interferon (IFN)-induced mRNA editing.

Anonymous Patient Answer

How serious can covid-19 be?

Since (1) the majority of cases of acute illness seen in New York hospitals are of low severity, and (2) the majority of people, including those most likely to be critically ill in intensive care units, will recover, people who might be at risk should be encouraged to resume everyday activities as soon as possible, including going back to work.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for COVID-19 by sharing your contact details with the study coordinator.